To elucidate the role of LRP1 in the AMP-IBP5-mediated amelioration of AD symptoms, we subcutaneously administered mouse RAP, an antagonist of LRP1, to AD mice to inhibit LRP1. Here, LRP1 is linked to Alzheimer disease.